Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation

References

• Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Eng J Med. 2015;372:621–30. doi:10.1056/NEJMoa1406470.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol. 2010;22:486–97. doi:10.1016/j.clon.2010.03.013.
   PubMed Web of Science ®Google Scholar
• Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39:1357–61. doi:10.1002/1097-0142(197704)39:4%3c1357::AID-CNCR2820390402%3e3.0.CO;2-C. PMID:856436.
   PubMed Web of Science ®Google Scholar
• Seto A, Sugitani I, Toda K, Kawabata K, Takahashi S, Saotome T. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. Surgery Today. 2015;45:221–6. doi:10.1007/s00595-013-0751-x. PMID:25734195.
   PubMed Web of Science ®Google Scholar
• Derbel O, Limem S, Segura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardière C. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 2011;11:469. doi:10.1186/1471-2407-11-469. PMID:22044775.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang WQ, Zhu H, Qian YY, Zhou L, Ren YJ, Ren XC, Zhang L, Liu XP, Liu CG, et al. Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol. 2014;87:562–70. doi:10.1016/j.bcp.2013.12.004. PMID:24345332.
   PubMed Web of Science ®Google Scholar
• Ranganath R, Shah MA, Shah AR. Anaplastic thyroid cancer. Curr Opin Endocrinol Diabetes Obesity. 2015;22:387–91. doi:10.1097/MED.0000000000000189.
   PubMed Web of Science ®Google Scholar
• Perri F, Lorenzo GD, Scarpati GD, Buonerba C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol. 2011;2:150–7. doi:10.5306/wjco.v2.i3.150. PMID:21611089.
   PubMedGoogle Scholar
• Shukla GC, Singh J, Barik S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3:83–92. PMID:22468167.
   PubMedGoogle Scholar
• Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215–22. doi:10.1097/PPO.0b013e318250c001. PMID:22647357.
   PubMed Web of Science ®Google Scholar
• Chen S, Li P, Li J, Wang Y, Du Y, Chen X, et al. MiR-144 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2015;35:997–1007. doi:10.1159/000369755.
   PubMed Web of Science ®Google Scholar
• Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis. 2013;34:454–63. doi:10.1093/carcin/bgs346. PMID:23125220.
   PubMed Web of Science ®Google Scholar
• Bao H, Li X, Li H, Xing H, Xu B, Zhang X, Liu Z. MicroRNA-144 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by targeting ZFX. J Biosci. 2017;42:103–11. doi:10.1007/s12038-016-9662-5. PMID:28229969.
   PubMed Web of Science ®Google Scholar
• He Q, Wang F, Honda T, Lindquist DM, Dillman JR, Timchenko NA, Redington AN. Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice. Tumour Biol. 2017;39:1010428317737729. doi:10.1177/1010428317737729. PMID:29072132.
   PubMedGoogle Scholar
• Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL, Zhao JC, Liang GM, Feng ZB, Chen G, Luo DZ. A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma. Onco Targets Ther. 2017;10:3405–19. doi:10.2147/OTT.S138143. PMID:28744145.
   PubMed Web of Science ®Google Scholar
• Liu F, Chen N, Xiao R, Wang W, Pan Z. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun. 2016;480:87–93. doi:10.1016/j.bbrc.2016.10.004. PMID:27717821.
   PubMed Web of Science ®Google Scholar
• Wu M, Huang C, Huang X, Liang R, Feng Y, Luo X. MicroRNA-144-3p suppresses tumor growth and angiogenesis by targeting SGK3 in hepatocellular carcinoma. Oncol Rep. 2017;38:2173–81. doi:10.3892/or.2017.5900. PMID:28849156.
   PubMed Web of Science ®Google Scholar
• Xiang C, Cui SP, Ke Y. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. J Huazhong Univ Sci Technolog Med Sci. 2016;36:186–92. doi:10.1007/s11596-016-1564-0. PMID:27072960.
   PubMed Web of Science ®Google Scholar
• Yu M, Lin Y, Zhou Y, Jin H, Hou B, Wu Z, Li Z, Jian Z, Sun J. MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4. Onco Targets Ther. 2016;9:4705–14. doi:10.2147/OTT.S88233. PMID:27536132.
   PubMed Web of Science ®Google Scholar
• Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, Ma X, Su C. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Cancer Res. 2017;36:40. doi:10.1186/s13046-017-0504-6. PMID:28270228.
   PubMed Web of Science ®Google Scholar
• Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, Xiu L, Li Y. Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine. 2015;48:566–74. doi:10.1007/s12020-014-0326-7. PMID:24968735.
   PubMed Web of Science ®Google Scholar
• Rossing M, Borup R, Henao R, Winther O, Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sørensen C, et al. Down-regulation of microRNAs controlling tumourigenic factors in follicular thyroid carcinoma. J Mol Endocrinol. 2012;48:11–23. doi:10.1530/JME-11-0039. PMID:22049245.
   PubMed Web of Science ®Google Scholar
• Xiao W, Lou N, Ruan H, Bao L, Xiong Z, Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al. Mir-144-3p promotes cell proliferation, metastasis, Sunitinib resistance in clear cell renal cell carcinoma by downregulating ARID1A. Cell Physiol Biochem 2017; 43:2420–33. doi:10.1159/000484395. PMID:29073615.
   PubMed Web of Science ®Google Scholar
• Zhou S, Ye W, Zhang Y, Yu D, Shao Q, Liang J, Zhang M. miR-144 reverses chemoresistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Am J Transl Res. 2016;8:2992–3002. PMID:27508019.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang S, Chen R, Wu Y, Zhang B, Huang S, Zhang J, Xiao F, Wang M, Liang Y. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. Biochem Biophys Res Commun. 2012;425:368–73. doi:10.1016/j.bbrc.2012.07.098. PMID:22842456.
   PubMed Web of Science ®Google Scholar
• Liu F, Wang J, Fu Q, Zhang X, Wang Y, Liu J, Huang J, Lv X. VEGF-activated miR-144 regulates autophagic survival of prostate cancer cells against Cisplatin. Tumour Biol. 2015;37;15627–33. doi:10.1007/s13277-015-4383-1. PMID:26566625.
   PubMedGoogle Scholar
• Madala SK, Korfhagen TR, Schmidt S, Davidson C, Edukulla R, Ikegami M, Violette SM, Weinreb PH, Sheppard D, Hardie WD. Inhibition of the alphavbeta6 integrin leads to limited alteration of TGF-alpha-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;306:L726–35. doi:10.1152/ajplung.00357.2013. PMID:24508732.
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res. 2000;259:293–9. doi:10.1006/excr.2000.4967. PMID:10942601.
   PubMed Web of Science ®Google Scholar
• Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10:8594–602. doi:10.1158/1078-0432.CCR-04-0690. PMID:15623643.
   PubMed Web of Science ®Google Scholar
• Chang JW, Yeh KY, Shen YC, Hsieh JJ, Chuang CK, Liao SK, Tsai LH, Wang CH. Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J Endocrinol. 2003;179:387–94. doi:10.1677/joe.0.1790387. PMID:14656208.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yi J, Ye R, Liu J, Duan Q, Xiao J, Liu F. miR-144 regulates transforming growth factor-beta1 iduced hepatic stellate cell activation in human fibrotic liver. Int J Clin Exp Pathol. 2015;8:3994–4000. PMID:26097586.
   PubMed Web of Science ®Google Scholar
• Xu Z, Ramachandran S, Gunasekaran M, Zhou F, Trulock E, Kreisel D, Hachem R, Mohanakumar T. MicroRNA-144 dysregulates the transforming growth factor-beta signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant. 2015;34:1154–62. doi:10.1016/j.healun.2015.03.021. PMID:25979625.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Hao S, Wang LL, Hu CY, Zhang S, Guo LJ, Zhang G, Gao B, Jiang Y, Tian WG, et al. Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-beta/Smad signaling pathway. Oncotarget. 2016;7:57903–18. PMID:27507052.
   PubMedGoogle Scholar
• Garcia-Rendueles AR, Rodrigues JS, Garcia-Rendueles ME, Suarez-Farina M, Perez-Romero S, Barreiro F, Bernabeu I, Rodriguez-Garcia J, Fugazzola L, Sakai T, et al. Rewiring of the apoptotic TGF-beta-SMAD/NFkappaB pathway through an oncogenic function of p27 in human papillary thyroid cancer. Oncogene. 2017;36:652–66. doi:10.1038/onc.2016.233. PMID:27452523.
   PubMed Web of Science ®Google Scholar
• Sun W, Xu Y, Zhao C, Hao F, Chen D, Guan J, Zhang K. Targeting TGF-beta1 suppresses survival of and invasion by anaplastic thyroid carcinoma cells. Am J Transl Res. 2017;9:1418–25. PMID:28386367.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen D, Hao FY, Zhang KJ. Targeting TGF-beta1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo. Eur Rev Med Pharmacol Sci. 2016;20:2581–7. PMID:27383308.
   PubMed Web of Science ®Google Scholar
• Yin Q, Liu S, Dong A, Mi X, Hao F, Zhang K. Targeting Transforming Growth Factor-Beta1 (TGF-beta1) inhibits tumorigenesis of anaplastic thyroid carcinoma cells through ERK1/2-NFkappakB-PUMA signaling. Med Sci Monit. 2016;22:2267–77. doi:10.12659/MSM.898702. PMID:27356491.
   PubMed Web of Science ®Google Scholar
• Zhang K, Liu X, Hao F, Dong A, Chen D. Targeting TGF-beta1 inhibits invasion of anaplastic thyroid carcinoma cell through SMAD2-dependent S100A4-MMP-2/9 signalling. Am J Transl Res. 2016;8:2196–209. PMID:27347327.
   PubMed Web of Science ®Google Scholar
• Rhee YH, Moon JH, Choi SH, Ahn JC. Low-level laser therapy promoted aggressive proliferation and angiogenesis through decreasing of transforming growth factor-beta1 and increasing of Akt/Hypoxia inducible Factor-1alpha in anaplastic thyroid cancer. Photomed Laser Surg. 2016;34:229–35. doi:10.1089/pho.2015.3968. PMID:27078192.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang F, Wang X, Tsai Y, Chuang KH, Keng PC, Lee SO, Chen Y. A FASN-TGF-beta1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer. Oncotarget. 2016;7:55543–54. PMID:27765901.
   PubMedGoogle Scholar
• Xu S, Xue C, Li J, Bi Y, Cao Y. Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway. J Virol. 2011;85:276–85. doi:10.1128/JVI.01392-10. PMID:20962090.
   PubMed Web of Science ®Google Scholar
• Tavassoli M, Soltaninia J, Rudnicka J, Mashanyare D, Johnson N, Gaken J. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1. Carcinogenesis. 2002;23:1569–75. doi:10.1093/carcin/23.10.1569. PMID:12376463.
   PubMed Web of Science ®Google Scholar
• Ooft ML, Braunius WW, Heus P, Stegeman I, van Diest PJ, Grolman W, Zuur CI, Willems SM. Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis. Biomarkers Med. 2015;9:997–1010. doi:10.2217/bmm.15.68.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. OncoTargets Therapy. 2016;9:6247–55. doi:10.2147/OTT.S103650. PMID:27785072.
   PubMed Web of Science ®Google Scholar
• Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, et al. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Applied Pharmacol. 2017;325:48–60. doi:10.1016/j.taap.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Fan Z, Huangfu X, Liu Z. Effect of autophagy on cisplatin-induced bladder cancer cell apoptosis. Panminerva Medica. 2017;59:1–8. PMID:27433879.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee GJ, Yi SS, Heo SH, Park CR, Nam HS, Cho MK, Lee SH. Cisplatin and resveratrol induce apoptosis and autophagy following oxidative stress in malignant mesothelioma cells. Food Chem Toxicol Int J Published Br Industrial Biol Res Association. 2016;97:96–107. doi:10.1016/j.fct.2016.08.033.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013;145:1133-43 e12. doi:10.1053/j.gastro.2013.07.048.
   Web of Science ®Google Scholar
• He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget. 2015;6:28867–81. doi:10.18632/oncotarget.4814. PMID:26311740.
   PubMedGoogle Scholar
• Gu H, Liu M, Ding C, Wang X, Wang R, Wu X, Fan R. Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. Cancer Med. 2016;5:1174–82. doi:10.1002/cam4.664. PMID:26990493.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhou L, Gao Q, Zhang A, Wei J, Hong D, Chu Y, Duan X, Zhang Y, Xu G, et al. MicroRNA-144-3p inhibits autophagy activation and enhances Bacillus Calmette-Guerin infection by targeting ATG4a in RAW264.7 macrophage cells. PloS One. 2017;12:e0179772. doi:10.1371/journal.pone.0179772. PMID:28636635.
   PubMed Web of Science ®Google Scholar
• Yuan TZ, Zhang HH, Lin XL, Yu JX, Yang QX, Liang Y, Deng J, Huang LJ, Zhang XP. microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2. Mol Med Reports. 2017;15:2223–8. doi:10.3892/mmr.2017.6233.
   PubMed Web of Science ®Google Scholar
• Ali SM, Yao M, Yao J, Wang J, Cheng Y, Schrock AB, Chirn GW, Chen H, Mu S, Gay L, et al. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Cancer. 2017;123:3628–37. doi:10.1002/cncr.30781. PMID:28581676.
   PubMed Web of Science ®Google Scholar
• Ren K, Liu QQ, An ZF, Zhang DP, Chen XH. MiR-144 functions as tumor suppressor by targeting PIM1 in gastric cancer. Eur Rev Med Pharmacological Sci. 2017;21:3028–37.
   PubMed Web of Science ®Google Scholar
• Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha. Mol Cancer. 2016;15:11. doi:10.1186/s12943-016-0496-4. PMID:26832151.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhang P, Lv A, Liu Y, Wang G. MiR-205 functions as a tumor suppressor via targeting TGF-alpha in osteosarcoma. Exp Mol Pathol. 2016;100:160–6. doi:10.1016/j.yexmp.2015.12.010. PMID:26708425.
   PubMed Web of Science ®Google Scholar
• Wu H, Liu Y, Shu XO, Cai Q. MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression. Carcinogenesis. 2016;37:567–75. doi:10.1093/carcin/bgw038. PMID:27207663.
   PubMed Web of Science ®Google Scholar